Shorter leukocyte telomere length is associated with distinct CSF biomarker dynamics across early AD stages in at-risk individuals.

INTRODUCTIONTelomere length (TL) is a hallmark of biological aging. Shorter TL has been linked to an increased risk of Alzheimers disease (AD), but its role in AD pathophysiology remains unclear. This study investigates the relationship between TL, longitudinal cerebrospinal fluid (CSF) AD biomarkers, and brain structure in cognitively unimpaired (CU) individuals at risk for AD. METHODSWe analyzed data from 346 middle-aged CU ALFA+ participants, measuring leukocyte TL (LTL) by qPCR. AD-related CSF biomarkers were measured at baseline and after 3 years. Stratified analyses by APOE-e4 and amyloid-tau (AT) status were conducted. RESULTSShorter LTL was associated with higher astrocytic reactivity and synaptic dysfunction biomarkers, as well as thicker cortex in AD-vulnerable regions. Astrocytic biomarkers mediated the LTL-cortical thickness association. In APOE-e4 carriers and AT-positive individuals, shorter LTL linked to higher p-tau181 and neurodegeneration markers. CONCLUSIONThese findings highlight telomere shortening as a potential contributor of early AD-related progression. HighlightsO_LIShorter leukocyte telomere length (LTL) was associated with higher levels of cerebrospinal fluid (CSF) GFAP, CSF S100B and CSF -synuclein, independently of amyloid and tau pathology. C_LIO_LIShorter LTL was associated with higher baseline CSF NfL and t-tau levels in the A+T- and A+T+ groups, respectively. C_LIO_LILTL association with brain structure was partially mediated by CSF biomarkers of astrocytic reactivity. C_LI Research in context1. Systematic review: Literature review was performed using traditional sources (e.g., PubMed). While the association between leukocyte telomere length (LTL) shortening and increased sporadic AD risk is well-documented, its role in AD pathogenesis remains unclear. These findings have been appropriately referenced. 2. Interpretation: In cognitively unimpaired adults at higher risk for AD, shorter LTL was associated with high AD-related cerebrospinal fluid (CSF) biomarkers, including p-tau181 and biomarkers of neurodegeneration, synaptic dysfunction, glial reactivity, and inflammation. These associations were either more pronounce or exclusively observed in APOE-e4 carriers and individuals with early AD pathology (measured by CSF A{beta}42/40 and p-tau181). Furthermore, increased astrocytic reactivity mediated the relationship between LTL and brain structure integrity. 3. Future directions: Further research is needed to understand the role of peripheral aging in AD pathology. Investigating how peripheral immune aging influences brain homeostasis and AD progression could help identify early targets of neuroinflammation and neurodegeneration.